Tether Freezes 22 Wallets Across Ethereum and Tron

TheCryptoTimesPublicado a 2025-10-17Actualizado a 2025-10-17

Tether, the company behind the popular stablecoin USDT, has frozen $13.4 million worth of USDT spread across 22 wallets on the Ethereum and Tron networks. 

Blockchain tracking firm MistTrack reported that the largest share of the frozen funds, $10.3 million, was held in a single Ethereum address ‘0xecbd8…’. Another wallet ‘TYzDebk…’ on Tron contained USDT worth approximately $1.4 million.

The company has carried out similar actions throughout the year. In June, it froze more than $12.3 million, and in April 2025, around 28.67 million USDT was frozen across 13 wallets. 

In March, Tether froze $28 million in USDT on the Russian crypto exchange Garantex, though blockchain analysis firm Global Ledger noted that the exchange still held $15 million in active funds.

In a September 15 statement, Tether said it has frozen over $3.2 billion in USDT connected to criminal activity, working with more than 290 law enforcement agencies in 59 countries. Over the past year, the company has blocked around 3,660 wallets.

Why the wallets are frozen

Tether usually freezes wallets when requested by authorities like the U.S. Department of Justice (DOJ), the Federal Bureau of Investigation (FBI), or other international agencies. 

Wallets linked to fraud, terrorism, sanctioned entities, or illegal markets may be blocked to stop the movement of funds. The company also keeps an eye on blockchain activity to follow anti-money-laundering and sanctions rules.

Not everyone agrees with Tether’s approach. Recently, Texas-based Riverstone Consulting filed a lawsuit, claiming the company wrongly froze $44.7 million in April, which affected their investments. Riverstone says Tether skipped formal international procedures, including the Bulgarian International Judicial Assistance Treaty, which requires requests to go through official channels.

Also Read: Tether Donates $250K to OpenSats for Bitcoin Ecosystem Growth


Mobile Only ImageMobile Only Image

Criptos en tendencia

Lecturas Relacionadas

JPMorgan Research Report Analysis: Moderna's INT Trial Meets Endpoints, but Market Already Priced In

On August 19, J.P. Morgan (JPM) published a research report analyzing Moderna's recent Phase III trial success for its Individualized Neoantigen Therapy (INT), developed in partnership with Merck, in adjuvant melanoma. The trial met its primary endpoint of significantly improved recurrence-free survival and the key secondary endpoint of distant metastasis-free survival. While JPM acknowledged the strong clinical value of these results, particularly the prevention of distant metastasis, the bank stated that this success was widely anticipated, with an 85% prior probability of success, and is already reflected in Moderna's current market valuation. Following the announcement, Moderna's stock rose in pre-market trading. However, JPM maintained its Underweight rating and $40 price target, implying approximately 36% downside from the current price of ~$63. The core rationale is that the success in adjuvant melanoma, a relatively small market in immuno-oncology, is fully priced in. Moderna's future valuation hinges entirely on INT's ability to demonstrate similar efficacy across broader cancer indications. JPM's valuation model incorporates only a modest risk-adjusted value (~$3/share) for the melanoma approval. Approximately $15/share of its target price is attributed to INT's potential in other cancer types. The report identifies upcoming data readouts in non-melanoma cancers (e.g., lung, head & neck, renal) as the critical variable that will determine the platform's ultimate value. Upside risks include better-than-expected data in these new indications, while downside risks involve clinical failures, regulatory delays, or commercial underperformance. In conclusion, JPM views the pre-market stock move as driven by short covering and trading sentiment rather than a fundamental re-rating. The bank remains bearish, arguing that Moderna must now prove INT's efficacy as a platform technology beyond melanoma to justify its current market cap.

marsbitHace 43 min(s)

JPMorgan Research Report Analysis: Moderna's INT Trial Meets Endpoints, but Market Already Priced In

marsbitHace 43 min(s)

Treasury Department Directly Intervenes to Suppress Long-Term Interest Rates

The article discusses the U.S. Treasury's recent direct intervention to suppress long-term bond yields through buyback operations. While distinct from traditional Yield Curve Control (YCC), this move is interpreted as direct government intervention in its own financing costs. The author emphasizes the short-term tactical nature of this action and contrasts it with the Federal Reserve's upcoming, potentially divergent, policy stance at Jackson Hole. The core issue is framed as a long-term U.S. strategic dilemma: managing high deficit levels. The analysis argues that deficit reduction cannot realistically come from spending cuts or traditional industries, but must rely on achieving higher economic growth driven by technological breakthroughs. Current monetary tightening, while possibly curbing yields and inflation in the short term, is seen as potentially counterproductive to this necessary long-term investment in technology and supply chain resilience. The piece draws historical parallels, placing the current intervention between the 2000-2002 Treasury buybacks (for liquidity) and larger-scale Fed-led "Operation Twist" maneuvers. The effectiveness of the Treasury's action is deemed limited without Federal Reserve cooperation, which would signify a more significant policy shift. Ultimately, the author views such technical, bureaucratic interventions as treating symptoms rather than the underlying disease of the U.S. economy's structural challenges and "K-shaped" divergence. The conclusion suggests that sustained yield suppression by the Fed, combined with specific geopolitical outcomes, could serve as a catalyst for a more profound discussion on broader U.S. and dollar trajectory.

marsbitHace 43 min(s)

Treasury Department Directly Intervenes to Suppress Long-Term Interest Rates

marsbitHace 43 min(s)

Trading

Spot

Artículos destacados

Cómo comprar TRX

¡Bienvenido a HTX.com! Hemos hecho que comprar TRON (TRX) sea simple y conveniente. Sigue nuestra guía paso a paso para iniciar tu viaje de criptos.Paso 1: crea tu cuenta HTXUtiliza tu correo electrónico o número de teléfono para registrarte y obtener una cuenta gratuita en HTX. Experimenta un proceso de registro sin complicaciones y desbloquea todas las funciones.Obtener mi cuentaPaso 2: ve a Comprar cripto y elige tu método de pagoTarjeta de crédito/débito: usa tu Visa o Mastercard para comprar TRON (TRX) al instante.Saldo: utiliza fondos del saldo de tu cuenta HTX para tradear sin problemas.Terceros: hemos agregado métodos de pago populares como Google Pay y Apple Pay para mejorar la comodidad.P2P: tradear directamente con otros usuarios en HTX.Over-the-Counter (OTC): ofrecemos servicios personalizados y tipos de cambio competitivos para los traders.Paso 3: guarda tu TRON (TRX)Después de comprar tu TRON (TRX), guárdalo en tu cuenta HTX. Alternativamente, puedes enviarlo a otro lugar mediante transferencia blockchain o utilizarlo para tradear otras criptomonedas.Paso 4: tradear TRON (TRX)Tradear fácilmente con TRON (TRX) en HTX's mercado spot. Simplemente accede a tu cuenta, selecciona tu par de trading, ejecuta tus trades y monitorea en tiempo real. Ofrecemos una experiencia fácil de usar tanto para principiantes como para traders experimentados.

2.0k Vistas totalesPublicado en 2024.12.10Actualizado en 2026.06.02

Cómo comprar TRX

Discusiones

Bienvenido a la comunidad de HTX. Aquí puedes mantenerte informado sobre los últimos desarrollos de la plataforma y acceder a análisis profesionales del mercado. A continuación se presentan las opiniones de los usuarios sobre el precio de TRX (TRX).

活动图片